OPK Insider Trading

Insider Ownership Percentage: 49.69%
Insider Buying (Last 12 Months): $4,631,852.32
Insider Selling (Last 12 Months): $23,874,134.15

OPKO Health Insider Trading History Chart

This chart shows the insider buying and selling history at OPKO Health by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$520kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

OPKO Health Share Price & Price History

Current Price: $1.41
Price Change: Price Decrease of -0.005 (-0.35%)
As of 04/29/2025 01:34 PM ET

This chart shows the closing price history over time for OPK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$1.41Closing price on 04/28/25:

SEC Filings (Institutional Ownership Changes) for OPKO Health (NASDAQ:OPK)

64.63% of OPKO Health stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OPK by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$903kbought$58ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal InflowsTotal Outflows
OPKO Health logo
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
Read More on OPKO Health

Today's Range

Now: $1.41
Low: $1.35
High: $1.41

50 Day Range

MA: $1.64
Low: $1.36
High: $1.94

52 Week Range

Now: $1.41
Low: $1.15
High: $2.04

Volume

1,195,680 shs

Average Volume

3,885,830 shs

Market Capitalization

$943.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.78

Who are the company insiders with the largest holdings of OPKO Health?

OPKO Health's top insider investors include:
  1. Phillip Md Et Al Frost (CEO)
  2. Jane Ph D Hsiao (Vice Chairman)
  3. Elias A Zerhouni (Vice Chairman)
  4. Steven D Rubin (VP)
  5. Opko Health, Inc (Major Shareholder)
  6. Gary J Nabel (Insider)
  7. Richard C Pfenniger Jr (Director)
  8. Richard M Krasno (Director)
Learn More about top insider investors at OPKO Health.

Who are the major institutional investors of OPKO Health?

OPKO Health's top institutional investors include:
  1. PFG Investments LLC — 0.18%
  2. Assenagon Asset Management S.A. — 0.14%
  3. Rhumbline Advisers — 0.07%
  4. SG Americas Securities LLC — 0.05%
  5. Exchange Traded Concepts LLC — 0.05%
  6. Teacher Retirement System of Texas — 0.01%
Learn More about top institutional investors of OPKO Health stock.

Which institutional investors are selling OPKO Health stock?

Within the previous quarter, OPK stock was sold by these institutional investors:
  1. Rhumbline Advisers
  2. Exchange Traded Concepts LLC

Which institutional investors are buying OPKO Health stock?

Within the previous quarter, OPK stock was purchased by institutional investors including:
  1. SG Americas Securities LLC
  2. Teacher Retirement System of Texas
  3. Assenagon Asset Management S.A.
  4. PFG Investments LLC
  5. Wealth Enhancement Advisory Services LLC
  6. Pallas Capital Advisors LLC
During the last year, these company insiders have bought OPKO Health stock:
  1. Phillip Md Et Al Frost (CEO)
  2. Jane Ph D Hsiao (Vice Chairman)
  3. Elias A Zerhouni (Vice Chairman)
  4. Steven D Rubin (VP)
  5. Opko Health, Inc (Major Shareholder)
  6. Gary J Nabel (Insider)
  7. Richard C Pfenniger Jr (Director)
Learn More investors buying OPKO Health stock.